Indeed Snapshot

Track NanoString Technologies reviews on Indeed to uncover insights on employee sentiment

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Profile Url Name Website Industry Description Revenue Headquarters location CEO Rating: CEO (%) Rating: CEO Responses Count Rating: Overall Happiness: Compensation score Happiness: Support score Happiness: Purpose score Happiness: Flexibility score Happiness: Energy score Happiness: Work Happiness score Happiness: Trust score Happiness: Learning score Happiness: Belonging score Happiness: Inclusion score Happiness: Overall score Happiness: Appreciation score Happiness: Achievement score Happiness: Responses Count Review Count Ratings Responses Count Rating: Culture & Values Rating: Compensation & Benefits Rating: Job Security & Advancement Rating: Senior Management Rating: Worklife Balance Interview: Duration Responses count Interview Duration Interview: Difficulty Responses count Interview Difficulty Interview: Experience Responses count Interview Experience Work Culture: Stressful (0) to Relaxed (1) Ratio Work Culture: Slow Paced (0) to Fast Paced (1) Ratio Work Culture: Competitive (0) to Collaborative (1) Ratio Date Added Date Updated Company Name Sector Industry
nasdaq:nstg https://www.indeed.com/cmp/nanostring-technologies Aug 29th, 2022 12:00AM Open NanoString Technologies Pharmaceutical & Biotechnology Listen to our CEO explain NanoString's role in the Life Sciences and Diagnostics space! http://mendelspod.com/podcasts/bringing-home-some-diagnostics-gold-brad-gray-nanostring-show-how-its-done/ NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics. RRv1_25M_100M Seattle 3.20 70.0 69.0 57.0 63.0 48.0 53.0 59.0 67.0 55.0 54.0 67.0 57.0 22.0 38.00 38.00 3.00 3.60 3.10 2.90 3.20 14.00 About two weeks 13.00 MEDIUM 14.00 FAVORABLE Aug 29th, 2022 12:21PM Aug 29th, 2022 12:21PM NanoString Technologies Health Care Pharmaceuticals & Biotechnology
nasdaq:nstg https://www.indeed.com/cmp/nanostring-technologies Aug 28th, 2022 12:00AM Open NanoString Technologies Pharmaceutical & Biotechnology Listen to our CEO explain NanoString's role in the Life Sciences and Diagnostics space! http://mendelspod.com/podcasts/bringing-home-some-diagnostics-gold-brad-gray-nanostring-show-how-its-done/ NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics. RRv1_25M_100M Seattle 3.20 70.0 69.0 57.0 63.0 48.0 53.0 59.0 67.0 55.0 54.0 67.0 57.0 22.0 38.00 38.00 3.00 3.60 3.10 2.90 3.20 14.00 About two weeks 13.00 MEDIUM 14.00 FAVORABLE Aug 28th, 2022 05:20AM Aug 28th, 2022 05:20AM NanoString Technologies Health Care Pharmaceuticals & Biotechnology
nasdaq:nstg https://www.indeed.com/cmp/nanostring-technologies Aug 27th, 2022 12:00AM Open NanoString Technologies Pharmaceutical & Biotechnology Listen to our CEO explain NanoString's role in the Life Sciences and Diagnostics space! http://mendelspod.com/podcasts/bringing-home-some-diagnostics-gold-brad-gray-nanostring-show-how-its-done/ NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics. RRv1_25M_100M Seattle 3.20 70.0 69.0 57.0 63.0 48.0 53.0 59.0 67.0 55.0 54.0 67.0 57.0 22.0 38.00 38.00 3.00 3.60 3.10 2.90 3.20 14.00 About two weeks 13.00 MEDIUM 14.00 FAVORABLE Aug 27th, 2022 04:39AM Aug 27th, 2022 04:39AM NanoString Technologies Health Care Pharmaceuticals & Biotechnology
nasdaq:nstg https://www.indeed.com/cmp/nanostring-technologies Aug 25th, 2022 12:00AM Open NanoString Technologies Pharmaceutical & Biotechnology Listen to our CEO explain NanoString's role in the Life Sciences and Diagnostics space! http://mendelspod.com/podcasts/bringing-home-some-diagnostics-gold-brad-gray-nanostring-show-how-its-done/ NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics. RRv1_25M_100M Seattle 3.20 70.0 69.0 57.0 63.0 48.0 53.0 59.0 67.0 55.0 54.0 67.0 57.0 22.0 38.00 38.00 3.00 3.60 3.10 2.90 3.20 14.00 About two weeks 13.00 MEDIUM 14.00 FAVORABLE Aug 25th, 2022 09:19AM Aug 25th, 2022 09:19AM NanoString Technologies Health Care Pharmaceuticals & Biotechnology
nasdaq:nstg https://www.indeed.com/cmp/nanostring-technologies Aug 23rd, 2022 12:00AM Open NanoString Technologies Pharmaceutical & Biotechnology Listen to our CEO explain NanoString's role in the Life Sciences and Diagnostics space! http://mendelspod.com/podcasts/bringing-home-some-diagnostics-gold-brad-gray-nanostring-show-how-its-done/ NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics. RRv1_25M_100M Seattle 3.20 70.0 69.0 57.0 63.0 48.0 53.0 59.0 67.0 55.0 54.0 67.0 57.0 22.0 38.00 38.00 3.00 3.60 3.10 2.90 3.20 14.00 About two weeks 13.00 MEDIUM 14.00 FAVORABLE Aug 23rd, 2022 11:12AM Aug 23rd, 2022 11:12AM NanoString Technologies Health Care Pharmaceuticals & Biotechnology
nasdaq:nstg https://www.indeed.com/cmp/nanostring-technologies Aug 21st, 2022 12:00AM Open NanoString Technologies Pharmaceutical & Biotechnology Listen to our CEO explain NanoString's role in the Life Sciences and Diagnostics space! http://mendelspod.com/podcasts/bringing-home-some-diagnostics-gold-brad-gray-nanostring-show-how-its-done/ NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics. RRv1_25M_100M Seattle 3.20 70.0 69.0 57.0 63.0 48.0 53.0 59.0 67.0 55.0 54.0 67.0 57.0 22.0 38.00 38.00 3.00 3.60 3.10 2.90 3.20 14.00 About two weeks 13.00 MEDIUM 14.00 FAVORABLE Aug 21st, 2022 12:56PM Aug 21st, 2022 12:56PM NanoString Technologies Health Care Pharmaceuticals & Biotechnology
nasdaq:nstg https://www.indeed.com/cmp/nanostring-technologies Aug 20th, 2022 12:00AM Open NanoString Technologies Pharmaceutical & Biotechnology Listen to our CEO explain NanoString's role in the Life Sciences and Diagnostics space! http://mendelspod.com/podcasts/bringing-home-some-diagnostics-gold-brad-gray-nanostring-show-how-its-done/ NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics. RRv1_25M_100M Seattle 3.20 70.0 69.0 57.0 63.0 48.0 53.0 59.0 67.0 55.0 54.0 67.0 57.0 22.0 38.00 38.00 3.00 3.60 3.10 2.90 3.20 14.00 About two weeks 13.00 MEDIUM 14.00 FAVORABLE Aug 20th, 2022 02:33PM Aug 20th, 2022 02:33PM NanoString Technologies Health Care Pharmaceuticals & Biotechnology
nasdaq:nstg https://www.indeed.com/cmp/nanostring-technologies Aug 19th, 2022 12:00AM Open NanoString Technologies Pharmaceutical & Biotechnology Listen to our CEO explain NanoString's role in the Life Sciences and Diagnostics space! http://mendelspod.com/podcasts/bringing-home-some-diagnostics-gold-brad-gray-nanostring-show-how-its-done/ NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics. RRv1_25M_100M Seattle 3.20 70.0 69.0 57.0 63.0 48.0 53.0 59.0 67.0 55.0 54.0 67.0 57.0 22.0 38.00 38.00 3.00 3.60 3.10 2.90 3.20 14.00 About two weeks 13.00 MEDIUM 14.00 FAVORABLE Aug 19th, 2022 12:56PM Aug 19th, 2022 12:56PM NanoString Technologies Health Care Pharmaceuticals & Biotechnology
nasdaq:nstg https://www.indeed.com/cmp/nanostring-technologies Aug 18th, 2022 12:00AM Open NanoString Technologies Pharmaceutical & Biotechnology Listen to our CEO explain NanoString's role in the Life Sciences and Diagnostics space! http://mendelspod.com/podcasts/bringing-home-some-diagnostics-gold-brad-gray-nanostring-show-how-its-done/ NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics. RRv1_25M_100M Seattle 3.20 70.0 69.0 57.0 63.0 48.0 53.0 59.0 67.0 55.0 54.0 67.0 57.0 22.0 38.00 38.00 3.00 3.60 3.10 2.90 3.20 14.00 About two weeks 13.00 MEDIUM 14.00 FAVORABLE Aug 18th, 2022 04:40AM Aug 18th, 2022 04:40AM NanoString Technologies Health Care Pharmaceuticals & Biotechnology
nasdaq:nstg https://www.indeed.com/cmp/nanostring-technologies Aug 17th, 2022 12:00AM Open NanoString Technologies Pharmaceutical & Biotechnology Listen to our CEO explain NanoString's role in the Life Sciences and Diagnostics space! http://mendelspod.com/podcasts/bringing-home-some-diagnostics-gold-brad-gray-nanostring-show-how-its-done/ NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics. RRv1_25M_100M Seattle 3.20 70.0 69.0 57.0 63.0 48.0 53.0 59.0 67.0 55.0 54.0 67.0 57.0 22.0 38.00 38.00 3.00 3.60 3.10 2.90 3.20 14.00 About two weeks 13.00 MEDIUM 14.00 FAVORABLE Aug 17th, 2022 10:19AM Aug 17th, 2022 10:19AM NanoString Technologies Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.